Pharma – API synthesis
With an increasing share of complex and chiral small molecules being developed by the Pharmaceutical industry, biocatalysis is developing as a way to shorten synthesis pathways, reduce costs and environmental footprint. In particular, enzymes are used for stereoselective synthesis and result in a better yield of the target product, or are used for chiral resolution.
Protéus services for API synthesis are integrated within SEQENS CDMO offer. We offer a full manufacturing services for API synthesis from early clinical phases to commercial scale, combining biocatalytic processes and « standard » chemical processes in order to offer to our cutomers the most competitive synthesis route.
|OUR Services: Biocatalytic process development|
For Pharma applications, as strict confidentiality is generally requested by our customers, the only examples we can provide are relative to SEQENS generic APIs production.
R-Baclofen is a selective GABAB receptor agonist. As such, it is a very important API. It is also under evaluation for treatment of alcohol use disorders. A biocatalytic process for the obtention of the pure R- enantiomer by desymetrization of a simple diester has been developed by Proteus.
D-Serine is the non-natural version of the aminoacid serine. It is used as a building block for the synthesis of several APIs. Its efficacy is proven in the treatment of tuberculosis and epilepsy, and as a neuromodulator in therapies for depression.
Enzyme production ( 15 m3 scale fermentor)
Industrial production (multi-ton scale):
- High specificity (ee > 99,9%)
- High productivity (345 g/L)